CN104490869B - III derivative of atractylodes lactone is in the drug for preparing application and anti-platelet aggregation in anti-platelet aggregation drug - Google Patents
III derivative of atractylodes lactone is in the drug for preparing application and anti-platelet aggregation in anti-platelet aggregation drug Download PDFInfo
- Publication number
- CN104490869B CN104490869B CN201410752500.0A CN201410752500A CN104490869B CN 104490869 B CN104490869 B CN 104490869B CN 201410752500 A CN201410752500 A CN 201410752500A CN 104490869 B CN104490869 B CN 104490869B
- Authority
- CN
- China
- Prior art keywords
- drug
- platelet aggregation
- agent
- dosage form
- application according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a kind of medicament for resisting platelet aggregation, including III derivative of atractylodes lactone as shown in structural formula 1:The invention further relates to application of III derivative of atractylodes lactone in the drug for preparing platelet aggregation-against.It is simple that the present invention provides a kind of composition, and the drug with platelet aggregation-against generated by the effective component extracts of the effective component of natural medicinal raw material or its medicinal raw material, with good effect, have no toxic side effect, be not likely to produce tolerance, and it is convenient to take be generally applicable to by platelet aggregation rate it is excessively high caused by blood viscousness and the problems such as thrombus.
Description
Technical field
The present invention relates to a kind of field of medicaments, more particularly to prepare the drug of III derivative platelet aggregation-against of atractylodes lactone
And application.
Background technique
Modern medicine believes that, the formation of thrombus and platelet aggregation rate is excessively high certain connection.
Thrombus starts from local clotting mechanism, and after the thrombosis of hyperfunction endarterium surface, thrombus is by the endothelium of hyperplasia
Cell is covered, and is incorporated to the disintegration of blood platelet and leucocyte in arterial wall thrombus and is released lipid and other active materials, by
Gradually form atheromatous plaque.The latter thinks that this disease starts from arterial intimal injury platelet activating factor (PAF) and increases, and blood platelet exists
Adherency is then assembled at this, and fibrin deposition then occurs and forms microthrombus.Some active materials are released after platelet aggregation,
Wherein thromboxane A2 (thromboxaneA2, TXA2) can fight vascular wall synthesis prostacyclin (prostacycline,
PGI2 make platelet disaggregation and angiectatic effect possessed by), and blood platelet is promoted further to assemble and vessel retraction；Blood
Platelet source growth factor (platelet derived growth factor) can stimulate smooth muscle hyperplasia shrink and to
Inner membrance is vacillated；Serotonin and fiber mother cell growth factor (fibroblast growth factor) can stimulate fiber female thin
Born of the same parents' smooth muscle cell and endotheli ocytosis adrenaline and adenosine diphosphate (ADP) can promote blood platelet further to assemble: factor Ⅷ
Adhere to blood platelet further；Platelet factor 4 (platelet factor 4) can make vessel retraction；Plasminogen activation
Agent mortifier (PAI), which makes the dissolution of thrombus be suppressed these substances, damages endothelial cell further so as to cause LDL entrance
Under inner membrance and inner membrance；So that monocyte is gathered in inner membrance and develops into foam cells；Make smooth muscle cell proliferation move into inner membrance to gulp down
Lipophagia matter；And endothelial cell proliferation is made all to be conducive to the formation of atherosis.
There is blood coagulation systems and anticoagulation system in blood of human body.Under normal circumstances, the two remain dynamic equilibrium with
Guarantee the proper flow of blood in the blood vessel, thrombus will not be formed, it is under special circumstances, narrow to wait damage if blood vessel has hardening
Hurt weather cold, excessive sweating, hypopiesia when lacking drinking-water, can make slow blood flow, pachyemia sticky, cause solidifying
It when blood hyperfunction or anticoagulating activity weaken, then can break this balance, make one in " easy bolt state ".Thrombotic disease can occur
From anywhere in blood vessel, thrombus flows in the blood vessels with blood, if stopped in cerebral artery vessel, it is dynamic to hinder brain
The circulation of arteries and veins normal blood is exactly cerebral thrombosis, thus cause ishemic stroke breaking-out, if plugging the coronary artery of heart,
Myocardial infarction can be then induced, in addition, there are also lower limb arterial thrombus lower-limb deep veins thrombus and pulmonary embolism etc..
Thrombosis, it is most of to will appear serious symptoms once falling ill, such as the aphasia hemiplegia of cerebral infarction；The play of myocardial infarction
Strong pareordia colic pain；The symptoms such as violent pectoralgia, expiratory dyspnea, hemoptysis caused by lung infraction；It can cause if lower limb form thrombus
Two have a pain in the leg pain, or coolness and intermittent claudication occur etc..The CR Critical heart, cerebral infarction and lung infraction can also cause sudden death.But
Sometimes also no obvious symptom, such as common Lower limb deep venous thrombosis, the only swollen discomfort of shank acid, many patients are thought as
Fatigue is caught a cold, and is taken exception to, thus is easy to miss best occasion for the treatment.Especially regrettably, many doctors are also easy this
Mistaken diagnosis, until when there is typical edema of lower extremity, it not only can be next difficult to treatment zone, it is also easy to leave sequelae.
Atractylodes lactone III (atractylodes lactone 3), alias atractyloide III, English name Atractylenolide- III, molecular formula
C15H20O3, molecular weight: 248.32, structural formula is as follows
Atractylodes lactone III is from compositae plant Rhizoma Atractylodis Macrocephalae Atractylodes macrocephala Koidz. dry root
Extract.In the research of the prior art, atractylodes lactone III has anti-inflammatory, antineoplastic action, which also has adjusting stomach
Intestines peristalsis and the function of promoting absorption of nutrient ingredients.
Summary of the invention
It is an object of the invention to solve the deficiencies in the prior art, it is simple to provide a kind of composition, and by natural medicinal raw material
Effective component or its medicinal raw material effective component extract combination made of with platelet aggregation-against drug.The medicine
Object has good effect, has no toxic side effect, is not likely to produce drug resistance, convenient to take, is generally applicable to excessively high by platelet aggregation rate
The problems such as caused blood viscousness and thrombus.
First aspect of the present invention is to provide a kind of drug of platelet aggregation-against, including the Rhizoma Atractylodis Macrocephalae as shown in structural formula 1
III derivative of lactone:
The drug of platelet aggregation-against of the present invention, it is preferred that the dosage form can be through gastrointestinal administration agent
It is type, injecting medicine-feeding form, respiratory tract administration dosage form, percutaneous drug delivery dosage form, mucosa delivery dosage form, any in cavity/canal drug administration dosage form
It is one or more of.
The drug of platelet aggregation-against of the present invention, it is preferred that described to be selected from powder, piece through gastrointestinal administration dosage form
Agent, granule, capsule, solution, emulsion, any one or a few in suspension.
The drug of platelet aggregation-against of the present invention, it is preferred that injecting medicine-feeding form is selected from intravenous injection, intramuscular note
It penetrates, be subcutaneously injected, any one or a few in intracutaneous injection and intracavitary administration.
The drug of platelet aggregation-against of the present invention, it is preferred that the respiratory tract administration dosage form is selected from spray, gas
Any one or a few in mist agent, powder spray.
The drug of platelet aggregation-against of the present invention, it is preferred that the percutaneous drug delivery dosage form is selected from solution, washes
Agent, liniment, ointment, emplastrum, paste, any one or a few in patch.
The drug of platelet aggregation-against of the present invention, it is preferred that the R1 is any one in substituents
Kind: hydrogen；The alkyl of straight chain or the C1-C10 of branching.
The drug of platelet aggregation-against of the present invention, it is preferred that the R2 is any one in substituents
Kind: hydrogen；The alkyl of straight chain or the C1-C10 of branching.
The drug of platelet aggregation-against of the present invention, it is preferred that the alkyl of the C1-C10 is more preferably C1-C8's
Alkyl, the more preferably alkyl of C1-C6, such as methyl, ethyl, n-propyl, isopropyl, normal-butyl, isobutyl group, tert-butyl, positive penta
Base, isopentyl, n-hexyl, isohesyl.
Wherein, the alkyl can be straight chained alkyl or branched-alkyl, more preferably straight chained alkyl.
The drug of platelet aggregation-against of the present invention, it is preferred that further include the second active constituent.
The drug of platelet aggregation-against of the present invention, it is preferred that the second active constituent is with platelet aggregation-against
Chinese medicine and Western medicine in any one or a few.
The drug of platelet aggregation-against of the present invention, it is preferred that second active constituent is selected from heparin, Hua Fa
Woods, aspirin, Dipyridamole, prostacyclin, Ticlopidine, persantine, Fenflumizole, any one in Sulfinpyrazone or several
Kind.
The drug of platelet aggregation-against of the present invention, it is preferred that second active constituent is selected from chuanxiong, red
Flower, radix paeoniae rubra, excrementum pteropi, thin Huang, Radix Angelicae Sinensis, ferulic acid, Rhizoma Chuanxiong, ligustrazine, Radix Salviae Miltiorrhizae, danshensu, Radix Curcumae essence, Radix Paeoniae Rubra 801, ginseng stilbene are multiple
Side, Artemisia anomala, trigone, Radix Angelicae Pubescentis, radix glycyrrhizae preparata, cattail pollen, evodia rutaecarpa, garlic, onion, Radix Curcumae, motherwort, black fungus, pueraria lobata, three
Seven, Caulis Spatholobi, dragon's blood, ilex pubescens, ginkgo leaf, fleabane flower, any one or a few in kadsurenone.
The drug of platelet aggregation-against of the present invention, it is preferred that by the drug with it is described pharmaceutically acceptable
Auxiliary material is mixed.
The drug of platelet aggregation-against of the present invention, it is preferred that the auxiliary material be selected from solvent, propellant, solubilizer,
Cosolvent, emulsifier, colorant, binder, disintegrating agent, filler, lubricant, wetting agent, osmotic pressure regulator, stabilizer,
Glidant, corrigent, preservative, suspending agent, coating material, aromatic, anti-binder, integrated agent, penetration enhancer, pH value tune
Save agent, buffer, plasticizer, surfactant, foaming agent, defoaming agent, thickener, inclusion agents, moisturizer, absorbent, dilution
Agent, flocculant and deflocculant, filter aid, release retarding agent in any one or a few.
The second aspect of the present invention is to provide a kind of III derivative of atractylodes lactone in the drug for preparing platelet aggregation-against
Application, it is preferred that be used to prepare the drug of the related disease of the excessively high initiation of platelet aggregation-against rate.
Wherein, III derivative of atractylodes lactone is as shown in above-mentioned structural formula 1.
Application of III derivative of atractylodes lactone in the drug for preparing platelet aggregation-against, it is preferred that be used to prepare prevention and treatment
Blood viscousness, heart infarction, cerebral infarction drug.
Beneficial effects of the present invention:
The present invention provides that a kind of composition is simple, and by the effective component of natural medicinal raw material or its medicinal raw material it is effective at
Point extract generate have treatment agglutinate rate of blood platelet it is excessively high cause related disease drug and drug preparation method and
Purposes has good effect, has no toxic side effect, be not likely to produce drug resistance, convenient to take, can be generally applicable to by platelet aggregation
Related disorder patients caused by rate is excessively high.
The present invention provide it is a kind for the treatment of by the excessively high initiation of platelet aggregation rate related disease drug and preparation method and
Purposes, drug are the extract of effective component, are taken without decocting, and are being prepared into tablet, capsule, pill, granule, are taking orally
It is easy to carry after liquid, it convenient for saving, and takes easily, any side effect is not found when normal dose is taken.
The present invention provide it is a kind for the treatment of by the excessively high initiation of platelet aggregation rate related disease drug and preparation method and
Purposes has the good property taken into account, except having very to the related disease of the excessively high initiation of the platelet aggregation rates such as blood viscousness, thrombus
Outside good curative effect, there are also anti-inflammatory, antitumor and have the function of adjusting gastrointestinal function and promote absorption of nutrient ingredients.
Detailed description of the invention
Fig. 1 is III platelet aggregation-against experimental result of atractylodes lactone；
Fig. 2 is the influence that atractylodes lactone III sprawls blood platelet；
Fig. 3 is the experimental result of the Western blotting of experiment described in Fig. 1；
Fig. 4 is the experimental result of the Western blotting of experiment described in Fig. 1
Fig. 5 is the contrast and experiment of atractylodes lactone III and acetylsalicylic acid platelet aggregation-against in vitro.
Specific embodiment
Technical solution of the present invention is described in further detail below with reference to embodiment.
It is atractylodes lactone III when R1, R2 are methyl, structural formula is
The present invention is verified below by specific pharmacy test:
One, test material prepares
Atractylodes lactone III, is dissolved in DMSO.
Two, experimental verification process
1. platelet aggregation test
(1) prepare blood platelet: the high concentration thrombocyte plasma in people source, preparation platelet count are 3 × 108/ mL, is placed in
In 37 DEG C of water-baths.
(2) the concentration gradient of III compound of atractylodes lactone: in 300uL blood platelet, the final concentration of compound is respectively 0.1 μ
m、0.5μm、1μm、5μm、10μm。
Compound is incubated for 3min in blood platelet before experiment starts, and setting resting, DMSO is as control in experiment.Make
Use thrombin as stimulant.Aggregation curve and aggregation rate are obtained by platelet aggregation instrument.
Experimental technique document:
Weng Z,Li D,Zhang L,et al.PTEN regulates collagen-induced platelet
activation.Blood.2010；116(14):2579-2581.
Liu J,Jackson CW,Gruppo RA,Jennings LK,Gartner TK.The beta3suunit of
the integrin alphallbbeta3regulates alphaIIb-mediated outside-in
signaling.Blood.2005；105(11):4345-4352.
(3) experimental result (see attached drawing 1):
From above the results showed that atractylodes lactone III has inhibiting effect to platelet aggregation, and in the Rhizoma Atractylodis Macrocephalae of high concentration
III inhibiting effect of ester is obvious.
2. blood platelet sprawls experiment
(1) prepare blood platelet: ibid, preparing blood platelet is 3 × 107/mL。
(2) the concentration gradient of III compound of atractylodes lactone: in every 100uL blood platelet, the final concentration of compound is respectively 1 μ
M,5μM,10μM.Compound is incubated for 3min in blood platelet.The blood platelet that drug-treated is crossed is layered on fibrin (40 μ g/
mL).By fluorescence antibody phalloidin, situation is sprawled in 100X oil microscopic observation blood platelet.
Experimental technique document:
Chen X,Zhang Y,Wang Y,et al.PDK1regulates platelet activation and
arterial thrombosis.Blood.2013；121(18):3718-3726.
(3) experimental result (see attached drawing 2): illustrate that atractylodes lactone III sprawls blood platelet and has an impact.
③Western blotting
After obtaining aggregation curve, blood platelet albumen sample (2 × SDS loading protein lysate) is collected, is passed through
The phosphorylation level of Western blotting detection relevant molecule.
Experimental result (see attached drawing 3, attached drawing 4) is as follows:
The phosphorylation level that the relevant molecule of signal path is detected by western blooting, when PI3K/Akt signal
Access is activated, then phosphorylation activation occurs for Akt molecule, to keep the enzyme in downstream, kinases, transcription factor etc. (such as GSK3) living
Change, eventually assemble platelet activation, and if Akt molecule phosphorylation level it is higher, extent of platelet aggregation is higher.It is real
Test as the result is shown: atractylodes lactone III influences the phosphorylation level of Akt molecule, and the variation of its concentration is to Akt molecule phosphorylation level
Influence it is consistent with the influence to extent of platelet aggregation.
4. the external platelet aggregation-against experiment of acetylsalicylic acid
(1) prepare blood platelet: ibid, preparing blood platelet is 3 × 108/mL；
(2) acetylsalicylic acid is dissolved in dehydrated alcohol, being diluted to concentration is 50mmol/L, uses thrombin
Stimulant stimulation, observes platelet aggregation situation.
Experimental result (see attached drawing 5) is as follows:
In the experiment in vitro of the same terms, acetylsalicylic acid thombin stimulation under, when at concentrations up to 150uM still without
Inhibiting effect, and low concentration (10uM) has inhibition platelet aggregation to atractylodes lactone III in vitro experiment.
Specific embodiments of the present invention are described in detail above, but it is merely an example, the present invention is simultaneously unlimited
It is formed on particular embodiments described above.To those skilled in the art, any couple of present invention carries out equivalent modifications and
Substitution is also all among scope of the invention.Therefore, without departing from the spirit and scope of the invention made by equal transformation and
Modification, all should be contained within the scope of the invention.
Claims (8)
1. III derivative of atractylodes lactone shown in a kind of structural formula 1 is in preparation prevention and treatment by the correlation of the excessively high initiation of platelet aggregation rate
Application in the drug of disease, the disease be pulmonary embolism, lower limb arterial thrombus, lower-limb deep veins thrombus,
Wherein, described R1, R2 separately any one in substituents: hydrogen；The C1-C10 of linear chain or branched chain
Alkyl.
2. application according to claim 1, which is characterized in that the R1 and R2 is respectively methyl.
3. application according to claim 1, which is characterized in that the dosage form of the drug be selected from through gastrointestinal administration dosage form,
It is injecting medicine-feeding form, respiratory tract administration dosage form, percutaneous drug delivery dosage form, mucosa delivery dosage form, any one in cavity/canal drug administration dosage form
Kind is several.
4. application according to claim 1, which is characterized in that the drug further includes the second active constituent, second work
Property ingredient be Chinese medicine and Western medicine with platelet aggregation-against in any one or a few.
5. application according to claim 4, which is characterized in that the Western medicine is selected from heparin, warfarin, aspirin, double
Any one or a few phonetic up to not, in prostacyclin, Ticlopidine, Fenflumizole, Sulfinpyrazone.
6. application according to claim 4, which is characterized in that the Chinese medicine be selected from Rhizoma Chuanxiong, safflower, radix paeoniae rubra, excrementum pteropi, when
Return, is Radix Salviae Miltiorrhizae, compound ginseng-astragalus, Artemisia anomala, trigone, Radix Angelicae Pubescentis, radix glycyrrhizae preparata, cattail pollen, evodia rutaecarpa, garlic, onion, Radix Curcumae, motherwort, black
Agaric, pueraria lobata, Radix Notoginseng, Caulis Spatholobi, dragon's blood, ilex pubescens, ginkgo leaf, any one or a few in fleabane flower.
7. application according to claim 1, which is characterized in that the drug also includes pharmaceutically acceptable auxiliary material.
8. application according to claim 7, which is characterized in that the auxiliary material is selected from solvent, propellant, solubilizer, hydrotropy
Agent, colorant, binder, disintegrating agent, filler, lubricant, wetting agent, osmotic pressure regulator, stabilizer, helps stream at emulsifier
Agent, corrigent, preservative, suspending agent, coating material, aromatic, anti-binder, integrated agent, penetration enhancer, pH value are adjusted
Agent, buffer, plasticizer, surfactant, foaming agent, defoaming agent, thickener, inclusion agents, moisturizer, absorbent, diluent,
Flocculant and deflocculant, filter aid, any one or a few in release retarding agent.
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410752500.0A CN104490869B (en) | 2014-12-09 | 2014-12-09 | III derivative of atractylodes lactone is in the drug for preparing application and anti-platelet aggregation in anti-platelet aggregation drug |
| EP15868066.0A EP3231422B1 (en) | 2014-12-09 | 2015-04-16 | Application of atractylenolide compound or derivative thereof and anti-platelet aggregation drug |
| US14/908,089 US9642832B2 (en) | 2014-12-09 | 2015-04-16 | Use of atractylenolide compound or its derivatives and a medicament for inhibiting platelet aggregation |
| PCT/CN2015/076743 WO2016090800A1 (en) | 2014-12-09 | 2015-04-16 | Application of atractylenolide compound or derivative thereof and anti-platelet aggregation drug |
| JP2017549568A JP2018507907A (en) | 2014-12-09 | 2015-04-16 | Application of atractylenolide compound or derivative thereof and platelet aggregation inhibitor |
| CN201580067226.6A CN107106538A (en) | 2014-12-09 | 2015-04-16 | The application of atractylodes lactone class compound or derivatives thereof and anti-platelet aggregation medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410752500.0A CN104490869B (en) | 2014-12-09 | 2014-12-09 | III derivative of atractylodes lactone is in the drug for preparing application and anti-platelet aggregation in anti-platelet aggregation drug |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104490869A CN104490869A (en) | 2015-04-08 |
| CN104490869B true CN104490869B (en) | 2019-05-31 |
Family
ID=52932385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410752500.0A Active CN104490869B (en) | 2014-12-09 | 2014-12-09 | III derivative of atractylodes lactone is in the drug for preparing application and anti-platelet aggregation in anti-platelet aggregation drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104490869B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016090800A1 (en) * | 2014-12-09 | 2016-06-16 | 上海交通大学医学院附属第三人民医院 | Application of atractylenolide compound or derivative thereof and anti-platelet aggregation drug |
| CN110507650B (en) * | 2019-10-12 | 2023-04-07 | 郑州大学第一附属医院 | Application of atractylenolide in preparation of antithrombotic drugs |
| CN110638755B (en) * | 2019-10-29 | 2021-05-11 | 江苏盈科生物制药有限公司 | Propofol medium-long chain fat emulsion and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102133222A (en) * | 2011-01-14 | 2011-07-27 | 广东药学院 | Compound Chinese medicine extract preventing arteriosclerosis and preparation method thereof |
| JP2013234177A (en) * | 2012-04-12 | 2013-11-21 | Kracie Seiyaku Kk | Cell death-inhibiting composition |
-
2014
- 2014-12-09 CN CN201410752500.0A patent/CN104490869B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102133222A (en) * | 2011-01-14 | 2011-07-27 | 广东药学院 | Compound Chinese medicine extract preventing arteriosclerosis and preparation method thereof |
| JP2013234177A (en) * | 2012-04-12 | 2013-11-21 | Kracie Seiyaku Kk | Cell death-inhibiting composition |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104490869A (en) | 2015-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104490868B (en) | Atractylenolide derivative is in the drug for preparing application and anti-platelet aggregation in anti-platelet aggregation drug | |
| Phillips et al. | Antihypertensive and vasodilator effects of methanolic and aqueous extracts of Tribulus terrestris in rats | |
| Cheng | Cardiovascular effects of Danshen | |
| Gorzalczany et al. | Artemisia copa aqueous extract as vasorelaxant and hypotensive agent | |
| CN104490869B (en) | III derivative of atractylodes lactone is in the drug for preparing application and anti-platelet aggregation in anti-platelet aggregation drug | |
| CN101264122A (en) | Hypericum extract, its making method and medicinal composition and use for treating diabetes | |
| CN103951645B (en) | The preparation method of Changbai larch extract and medicinal use | |
| CN104138377A (en) | A pharmaceutical composition treating severe high-altitude diseases | |
| CN100389795C (en) | Traditional Chinese medicine prepn. used for treating apoplexia and obstruction of qi in the chest, and its prepn. method | |
| EP3700519A1 (en) | Cannabinoid compositions and methods of use therof | |
| Jia-Yi et al. | Effect and mechanism of Qishen Yiqi Pills on adriamycin-induced cardiomyopathy in mice | |
| CN104147032B (en) | A kind of pharmaceutical composition for preventing and treating cerebral infarction relevant disease and its production and use | |
| CN106309671B (en) | Longnan of Gansu Province Z-bungeanum Maxim extract components and preparation method thereof and detection method | |
| CN101347424A (en) | Use of luteolin in preparing anticomplement medicament | |
| Yarnell et al. | Plant coumarins: Myths and realities | |
| CN1977878A (en) | Chinese medicine composition and its use | |
| CN102125662B (en) | Compound traditional Chinese medicine for treating apoplexia and preparation method and application thereof | |
| CN107106538A (en) | The application of atractylodes lactone class compound or derivatives thereof and anti-platelet aggregation medicine | |
| CN105687262A (en) | Folium ginkgo tincture and preparing method thereof | |
| CN100484563C (en) | Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| Baisch et al. | Endothelium-dependent vasorelaxing activity of aqueous extracts of lyophilized seeds of Casimiroa edulis (AECe) on rat mesenteric arterial bed | |
| CN108379311A (en) | A kind of preparation method and applications of Nitraria sibirica leaves extract | |
| Law et al. | “Lemongrass” and its applications for the treatment of hypertension | |
| CN103599146B (en) | A kind of preparation method of diuretic compositions and purposes | |
| CN103933386B (en) | Compound hemophiliac capsule used for treating hemophilia and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210528 Address after: 200011 No. 639, manufacturing Bureau Road, Shanghai, Huangpu District Patentee after: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Address before: 201900 No. 280, Mohe County Road, Shanghai, Baoshan District Patentee before: THE THIRD AFFILIATED PEOPLE'S HOSITAL OF SHANGHAIJIAO TONG University SCHOOL OF MEDICINE |
|
| TR01 | Transfer of patent right |